Recent advances in systemic therapy for breast cancer

Current Opinion in Oncology

Volumn 10, Issue 6, 1998, Pages 517-522

  Claire Dees, E ^a   Kennedy, M John ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTHRACYCLINE; ANTIBODY; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; HYDROCORTISONE; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; PACLITAXEL; RAZOXANE; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DIARRHEA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; ONCOGENE NEU; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 15144342067     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199811000-00007     Document Type: Review

References (39)

1. Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, et al.: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer [abstract]. Proc Am Soc Clin Oncol 1998, 17:101. This is the first trial to find any adjuvant regimen better than four cycles of standard-dose AC.
2. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickersham DL, et al.: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997, 89:1673-1682. This trial shows benefit from the addition of chemotherapy to hormonal adjuvant therapy women with node-negative, estrogen receptor-positive breast cancer.
3. International Breast Cancer Study Group: Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive post-menopausal breast cancer patients. J Clin Oncol 1997, 15:1385-1394. This trial shows benefit from the addition of chemotherapy to hormonal adjuvant therapy in postmenopausal women with node-positive breast cancer.
4. Albain K, Green S, Osborne K, Cobau C, Levine E, Ingle J, et al.: Tamoxifen (T) versus cyclophosphamide, adriamycin, and 5-FU plus either concurrent or seqential T in postmenopausal, receptor(+), node(+) breast cancer: a Southwest Oncology Group phase III intergroup trial [abstract]. Proc Am Soc Clin Oncol 1997, 16:128.
5. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from NSABP B-18. J Clin Oncol 1997, 15:2483-2493. Neoadjuvant chemotherapy may make breast-conserving surgery more often possible in patients with large tumors, but it has not yet been shown to improve survival.
6. Bonadonna G, Valagussa P Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998, 16:93-100. Neoadjuvant chemotherapy may make breast-conserving surgery more often possible in patients with large tumors, but it has not yet been shown to improve survival.
7. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al.: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997, 15:1318-1332.
8. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997, 15:1333-1340.
9. Nabholtz JM, Thuerlimann B, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, et al.: Taxotere vs mitomycin C plus vinblastine in patients with metastatic breast cancer who have failed an anthracycline-containing regimen [abstract]. Breast Cancer Res Treat 1997, 46:93.
10. Adachi I, Watanabe T, Takashima S, Norabayashi M, Horikoshi N, Aoyama H, Taguchi T: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996, 73:210-216.
11. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al.: Phase III study of taxotere vs doxorubicin in patients with metastatic breast cancer who have failed and alkylating containing regimen [abstract]. Breast Cancer Res Treat 1997, 46:23. A phase III trial showing docetaxel superior to doxorubicin in patients with metastatic breast cancer.
12. Bernard A, Antoine E-C, Gozy M, Benhammouda A, Youssef A, Auclerc G, et al.: Docetaxel and cisplatin combination in anthracycline-pretreated advanced breast cancer: preliminary results of a phase II study [abstract]. Breast Cancer Res Treat 1997, 46:58.
13. Sledge GW, Neuberg D, Ingle J, Martino S, Wood W: Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1997, 16:1a.
14. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, et al.: Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996, 14:1858-1867.
15. Winer E, Berry D, Duggan D, Henderson IC, Cirrincione C, Cooper R, Norton L: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: results from CALGB 9342 [abstract]. Proc Am Soc Clin Oncol 1998, 17:101.
16. Holmes FA, Valero V, Buzdar AU, Booser DJ, Winn R, Tolcher A, et al.: Final results: randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients with metastatic breast cancer (MBC). The long and short of it [abstract]. Proc Am Soc Clin Oncol 1998, 17:110.
17. Mamounas E, Brown A, Smith R, Lembersky B, Fisher B, Wickerham DL, et al.: Effect of taxol duration of infusion in advanced breast cancer (ABC): results from B-26 trial comparing 3-to 24-hour infusion of high-dose taxol [abstract]. Proc Am Soc Clin Oncol 1998, 17:101.
18. Seidman AD, Hudis CA, McCaffrey J, Tong W, Currie V, Moynahan ME, et al.: Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer. Semin Oncol 1997, 24(supp 17): S17-72-S17-76.
19. Buzdar A, Jonat W, Howell A, Yin H, Lee D: Significant improved survival with Arimidaex (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials [abstract]. Proc Am Soc Clin Oncol 1997, 16:156. Third-generation aromatase inhibitors have recently replaced megestrol acetate as second-line hormonal therapy.
20. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci RL, Bellmund J, et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megesterol acetate. J Clin Oncol 1998, 16:453-461. Letrozole was superior to megestrol acetate regarding objective response, duration of response, time to treatment failure, performance status, and tolerability.
21. Pyrhonen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, et al.: Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase II study. Br J Cancer 1997, 76:270-277.
22. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmen J, Eastern European Study Group: A phase II comparison of two toremifene doses to tamoxifen in post menopausal women with advanced breast cancer. Breast Cancer Res Treat 1997, 45:251-262.
23. Byrne MJ, Gebski V, Forbes J, Tattersall MHN, Simes RJ, Coates AS, et al.: Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase II randomized trial. J Clin Oncol 1997, 15:3141-3148.
24. Russell CA, Green SJ, O'Sullivan J, Hynes HE, Budd GT, Congdon JE, et al.: Megestrol acetate and ammoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol 1997, 15:2494-2501.
25. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984, 2:1281-1288.
26. Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, et al.: High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997, 15:1870-1879.
27. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN: Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997, 15:3171-3177. The selection process appears to have significant impact on the outcome of patients in HDCT trials as compared with historical control subjects.
28. Garcia-Carbonero R, Hidalgo M, Paz-Ares L, Calzas J, Gomez H, Guerra JA, et al.: Patient selection in high-dose chemotherapy trials: relevance to high-risk breast cancer. J Clin Oncol 1997, 15:3178-3184. This article and that of Rahman et al. (J Clin Oncol 1997, 15:3171-3177) suggest that that promising results from phase II trials of high-dose therapy with transplantation for metastatic breast cancer may be due in part to selection of patients with better prognoses.
29. Crump M, Goss PE, Prince M, Girouard C: Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 1996, 14:66-69.
30. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Konig CCE, et al.: A randomized trial of high-dose chemotherapy and hematopoietic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement [abstract]. Proc Am Soc Clin Oncol 1998, 17:123. This small randomized trial showed no benefit from high-dose therapy compared with conventional chemotherapy in the adjuvant setting for patients with high-risk breast cancer.
31. Hortobagyi GN, Buzdar AU, Champlin R, Gajewski J, Holmes FA, Booser D, et al.: Lack of efficacy of adjuvant high-dose tandem combination chemotherapy for high-risk primary breast cancer (HRPBC): a randomized trial [abstract]. Proc Am Soc Clin Oncol 1998, 17:123. This small randomized trial showed no benefit from high-dose therapy compared with conventional chemotherapy in the adjuvant setting for patients with high-risk breast cancer.
32. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al.: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1998, 17:97.
33. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, et al.: Addition of Herceptin (humanized ant-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled phase III trial [abstract]. Proc Am Soc Clin Oncol 1998, 17:98. Randomized trial in which women with metastatic breast cancer received, in addition to AC or paclitaxel, Herceptin or no further therapy. Those treated with Herceptin had superior response rates.
34. Bianco AR, deLaurentiis M, Carlomagno C, Lauria R, Petrella G, et al.: 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erb-b2 expression and tamoxifen efficacy [abstract]. Proc Am Soc Clin Oncol 1998, 17:97.
35. Ravdin PM, Green S, Albain KS, Boucher V, Ingle J, Pritchard K, et al.: Initial report of the SWOG biological correlative study of c-erb-b2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen alone [abstract]. Proc Am Soc Clin Oncol 1998, 17:97.
36. Blum JL, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Burger HU, et al.: A multicenter phase II trial of xeloda (capecitabine) in paclitaxel-refractory metastatic breast cancer(MBC) [abstract]. Proc Am Soc Clin Oncol 1998, 17:125.
37. O'Shaughnessy J, Moiseyenko V, Bell D, Nabholtz JM, Miles D, Gorbunova V, et al.: A randomized phase II study of xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged >55 years [abstract]. Proc Am Soc Clin Oncol 1998, 17:103.
38. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996, 335:1785-1791.
39. Powles TJ, Paterson AHG, Nevantaus A, Legault S, Pajunene M, et al.: Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer [abstract]. Proc Am Soc Clin Oncol 1998, 17:123. Evidence that the bisphosphonates, used in the adjuvant setting after primary treatment for operable breast cancer, can reduce the incidence of bone metastases in postmenopausal women.